144 related articles for article (PubMed ID: 36539557)
1. Inhibition of CD39 unleashes macrophage antibody-dependent cellular phagocytosis against B-cell lymphoma.
Casey M; Segawa K; Law SC; Sabdia MB; Nowlan B; Salik B; Lee C; Winterford C; Pearson S; Madore J; Dougall WC; Gandhi MK; Nakamura K
Leukemia; 2023 Feb; 37(2):379-387. PubMed ID: 36539557
[TBL] [Abstract][Full Text] [Related]
2. Targeting an adenosine-mediated "don't eat me signal" augments anti-lymphoma immunity by anti-CD20 monoclonal antibody.
Nakamura K; Casey M; Oey H; Vari F; Stagg J; Gandhi MK; Smyth MJ
Leukemia; 2020 Oct; 34(10):2708-2721. PubMed ID: 32269319
[TBL] [Abstract][Full Text] [Related]
3. CD47 Expression Defines Efficacy of Rituximab with CHOP in Non-Germinal Center B-cell (Non-GCB) Diffuse Large B-cell Lymphoma Patients (DLBCL), but Not in GCB DLBCL.
Bouwstra R; He Y; de Boer J; Kooistra H; Cendrowicz E; Fehrmann RSN; Ammatuna E; Zu Eulenburg C; Nijland M; Huls G; Bremer E; van Meerten T
Cancer Immunol Res; 2019 Oct; 7(10):1663-1671. PubMed ID: 31409608
[TBL] [Abstract][Full Text] [Related]
4. Dual checkpoint blockade of CD47 and LILRB1 enhances CD20 antibody-dependent phagocytosis of lymphoma cells by macrophages.
Zeller T; Lutz S; Münnich IA; Windisch R; Hilger P; Herold T; Tahiri N; Banck JC; Weigert O; Moosmann A; von Bergwelt-Baildon M; Flamann C; Bruns H; Wichmann C; Baumann N; Valerius T; Schewe DM; Peipp M; Rösner T; Humpe A; Kellner C
Front Immunol; 2022; 13():929339. PubMed ID: 36389667
[TBL] [Abstract][Full Text] [Related]
5. slan
Vermi W; Micheletti A; Finotti G; Tecchio C; Calzetti F; Costa S; Bugatti M; Calza S; Agostinelli C; Pileri S; Balzarini P; Tucci A; Rossi G; Furlani L; Todeschini G; Zamò A; Facchetti F; Lorenzi L; Lonardi S; Cassatella MA
Cancer Res; 2018 Jul; 78(13):3544-3559. PubMed ID: 29748373
[TBL] [Abstract][Full Text] [Related]
6. CD39 limits P2X7 receptor inflammatory signaling and attenuates sepsis-induced liver injury.
Savio LEB; de Andrade Mello P; Figliuolo VR; de Avelar Almeida TF; Santana PT; Oliveira SDS; Silva CLM; Feldbrügge L; Csizmadia E; Minshall RD; Longhi MS; Wu Y; Robson SC; Coutinho-Silva R
J Hepatol; 2017 Oct; 67(4):716-726. PubMed ID: 28554875
[TBL] [Abstract][Full Text] [Related]
7. Effects of blocking CD24 and CD47 'don't eat me' signals in combination with rituximab in mantle-cell lymphoma and chronic lymphocytic leukaemia.
Aroldi A; Mauri M; Ramazzotti D; Villa M; Malighetti F; Crippa V; Cocito F; Borella C; Bossi E; Steidl C; Scollo C; Voena C; Chiarle R; Mologni L; Piazza R; Gambacorti-Passerini C
J Cell Mol Med; 2023 Oct; 27(20):3053-3064. PubMed ID: 37654003
[TBL] [Abstract][Full Text] [Related]
8. Targeting CD39 in Cancer Reveals an Extracellular ATP- and Inflammasome-Driven Tumor Immunity.
Li XY; Moesta AK; Xiao C; Nakamura K; Casey M; Zhang H; Madore J; Lepletier A; Aguilera AR; Sundarrajan A; Jacoberger-Foissac C; Wong C; Dela Cruz T; Welch M; Lerner AG; Spatola BN; Soros VB; Corbin J; Anderson AC; Effern M; Hölzel M; Robson SC; Johnston RL; Waddell N; Smith C; Bald T; Geetha N; Beers C; Teng MWL; Smyth MJ
Cancer Discov; 2019 Dec; 9(12):1754-1773. PubMed ID: 31699796
[TBL] [Abstract][Full Text] [Related]
9. CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma.
Advani R; Flinn I; Popplewell L; Forero A; Bartlett NL; Ghosh N; Kline J; Roschewski M; LaCasce A; Collins GP; Tran T; Lynn J; Chen JY; Volkmer JP; Agoram B; Huang J; Majeti R; Weissman IL; Takimoto CH; Chao MP; Smith SM
N Engl J Med; 2018 Nov; 379(18):1711-1721. PubMed ID: 30380386
[TBL] [Abstract][Full Text] [Related]
10. DSP107 combines inhibition of CD47/SIRPα axis with activation of 4-1BB to trigger anticancer immunity.
Cendrowicz E; Jacob L; Greenwald S; Tamir A; Pecker I; Tabakman R; Ghantous L; Tamir L; Kahn R; Avichzer J; Aronin A; Amsili S; Zorde-Khvalevsky E; Gozlan Y; Vlaming M; Huls G; van Meerten T; Dranitzki ME; Foley-Comer A; Pereg Y; Peled A; Chajut A; Bremer E
J Exp Clin Cancer Res; 2022 Mar; 41(1):97. PubMed ID: 35287686
[TBL] [Abstract][Full Text] [Related]
11. Identification and characterization of ecto-nucleoside triphosphate diphosphohydrolase 1 (CD39) involved in regulating extracellular ATP-mediated innate immune responses in Japanese flounder (Paralichthys olivaceus).
Li S; Chen X; Wang N; Li J; Feng Y; Sun J
Mol Immunol; 2019 Aug; 112():10-21. PubMed ID: 31075558
[TBL] [Abstract][Full Text] [Related]
12. Combination of CD47 and signal-regulatory protein-α constituting the "don't eat me signal" is a prognostic factor in diffuse large B-cell lymphoma.
Kazama R; Miyoshi H; Takeuchi M; Miyawaki K; Nakashima K; Yoshida N; Kawamoto K; Yanagida E; Yamada K; Umeno T; Suzuki T; Kato K; Takizawa J; Seto M; Akashi K; Ohshima K
Cancer Sci; 2020 Jul; 111(7):2608-2619. PubMed ID: 32342603
[TBL] [Abstract][Full Text] [Related]
13. Berberine exerts anti-tumor activity in diffuse large B-cell lymphoma by modulating c-myc/CD47 axis.
Ren S; Cai Y; Hu S; Liu J; Zhao Y; Ding M; Chen X; Zhan L; Zhou X; Wang X
Biochem Pharmacol; 2021 Jun; 188():114576. PubMed ID: 33930347
[TBL] [Abstract][Full Text] [Related]
14. The yin and yang functions of extracellular ATP and adenosine in tumor immunity.
Feng LL; Cai YQ; Zhu MC; Xing LJ; Wang X
Cancer Cell Int; 2020; 20():110. PubMed ID: 32280302
[TBL] [Abstract][Full Text] [Related]
15. Activity of tafasitamab in combination with rituximab in subtypes of aggressive lymphoma.
Patra-Kneuer M; Chang G; Xu W; Augsberger C; Grau M; Zapukhlyak M; Ilieva K; Landgraf K; Mangelberger-Eberl D; Yousefi K; Berning P; Kurz KS; Ott G; Klener P; Khandanpour C; Horna P; Schanzer J; Steidl S; Endell J; Heitmüller C; Lenz G
Front Immunol; 2023; 14():1220558. PubMed ID: 37600821
[TBL] [Abstract][Full Text] [Related]
16. Combining CD47 blockade with trastuzumab eliminates HER2-positive breast cancer cells and overcomes trastuzumab tolerance.
Upton R; Banuelos A; Feng D; Biswas T; Kao K; McKenna K; Willingham S; Ho PY; Rosental B; Tal MC; Raveh T; Volkmer JP; Pegram MD; Weissman IL
Proc Natl Acad Sci U S A; 2021 Jul; 118(29):. PubMed ID: 34257155
[TBL] [Abstract][Full Text] [Related]
17. Combined strategies for effective cancer immunotherapy with a novel anti-CD47 monoclonal antibody.
Ni H; Cao L; Wu Z; Wang L; Zhou S; Guo X; Gao Y; Jing H; Wu M; Liu Y; Ding J; Zhang P; Zhou Y; Chen B; Xiong Y; Sun J; Prinz B; Baruah H; Geoghegan J; Yu M; Wu W; Liu J
Cancer Immunol Immunother; 2022 Feb; 71(2):353-363. PubMed ID: 34165607
[TBL] [Abstract][Full Text] [Related]
18. Characterization of AB598, a CD39 Enzymatic Inhibitory Antibody for the Treatment of Solid Tumors.
Anderson AE; Parashar K; Jin K; Clor J; Stagnaro CE; Vani U; Singh J; Chen A; Guan Y; Talukdar P; Sathishkumar P; Juat DJ; Singh H; Kushwaha R; Zhao X; Kaplan A; Seitz L; Walters MJ; Fernandez-Salas E; Walker NPC; Bowman CE
Mol Cancer Ther; 2024 May; ():. PubMed ID: 38797955
[TBL] [Abstract][Full Text] [Related]
19. Development of combinatorial antibody therapies for diffuse large B cell lymphoma.
Geanes ES; Krepel SA; McLennan R; Pierce S; Khanal S; Bradley T
Front Med (Lausanne); 2022; 9():1034594. PubMed ID: 36353222
[TBL] [Abstract][Full Text] [Related]
20. Amplification of spatially isolated adenosine pathway by tumor-macrophage interaction induces anti-PD1 resistance in hepatocellular carcinoma.
Lu JC; Zhang PF; Huang XY; Guo XJ; Gao C; Zeng HY; Zheng YM; Wang SW; Cai JB; Sun QM; Shi YH; Zhou J; Ke AW; Shi GM; Fan J
J Hematol Oncol; 2021 Nov; 14(1):200. PubMed ID: 34838121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
